Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/37433
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zlomke, Christin | - |
dc.contributor.author | Albrecht, Johannes | - |
dc.contributor.author | Mäder, Karsten | - |
dc.date.accessioned | 2021-07-26T08:22:31Z | - |
dc.date.available | 2021-07-26T08:22:31Z | - |
dc.date.issued | 2020 | - |
dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/37676 | - |
dc.identifier.uri | http://dx.doi.org/10.25673/37433 | - |
dc.description.abstract | The aim of the study was to develop nicardipine loaded phospholipid extrudates as an alternative for PLA/PLGA-based implants for the prevention of cerebral vasospasms. Extrudates of different mixtures of saturated and unsaturated phosphatidylcholine (PC) were produced and characterized by DSC, microscopy and texture analysis. Single phospholipid components were identified by ELSD-HPLC. Extrudates of 2 mm diameter were obtained by twin screw extrusion temperatures below 50 °C. The ratio of unsaturated and saturated phosphatidylcholine components determines the physicochemical properties of the extrudates as well as the rate of erosion. Nicardipine loaded phospholipids extrudates released the drug over several weeks in vitro. The phospholipid composition of the remaining extrudate changed during the release, the content of unsaturated phospholipids decreased faster compared to the saturated ones. In conclusion, solid phospholipid extrudates are promising materials for the development of new parenteral controlled release systems. | eng |
dc.description.sponsorship | Publikationsfond MLU | - |
dc.language.iso | eng | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject.ddc | 615 | - |
dc.title | Nicardipine loaded solid phospholipid extrudates for the prevention of cerebral vasospasms : in vitro characterization | eng |
dc.type | Article | - |
local.versionType | publishedVersion | - |
local.bibliographicCitation.journaltitle | Pharmaceutics | - |
local.bibliographicCitation.volume | 12 | - |
local.bibliographicCitation.issue | 9 | - |
local.bibliographicCitation.publishername | MDPI | - |
local.bibliographicCitation.publisherplace | Basel | - |
local.bibliographicCitation.doi | 10.3390/pharmaceutics12090817 | - |
local.subject.keywords | phospholipid; phosphatidylcholine; lecithin; controlled release; implant; extrusion; parenteral; biodegradable; nicardipine; dihydropyridine | - |
local.openaccess | true | - |
dc.identifier.ppn | 1728493560 | - |
local.bibliographicCitation.year | 2020 | - |
cbs.sru.importDate | 2021-07-26T08:21:24Z | - |
local.bibliographicCitation | Enthalten in Pharmaceutics - Basel : MDPI, 2009 | - |
local.accessrights.dnb | free | - |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
pharmaceutics-12-00817.pdf | 6.67 MB | Adobe PDF | View/Open |